Asset Details
Do you wish to reserve the book?
Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease
Do you wish to request the book?
Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease
2025
Overview
Objective
We aimed to investigate the efficacy and safety of a regimen combining bedaquiline and clofazimine in the treatment of refractory nontuberculous mycobacterial lung disease caused by
Mycobacterium avium complex
(MAC) or
Mycobacterium abscessus
subsp.
abscessus
(here Mab).
Methods
In this open-label, prospective pilot study, patients with refractory non-tuberculous mycobacterial pulmonary disease (NTM-PD) were enrolled to receive a regimen of bedaquiline and clofazimine alongside individualized background therapies. No control group was established in the study. Sputum samples were collected for culture at baseline (prior to treatment initiation) and then monthly thereafter. After the initial 6-month period, sputum collection frequency was reduced to every two months until trial completion. The primary end-point was sputum culture conversion rate. However, due to insufficient patient enrollment, we present these findings as a case series.
Results
A total of 11 patients were enrolled in this study, including 8 cases infected with
Mycobacterium abscessus
subsp.
abscessus
, 2 with
Mycobacterium avium
, and 1 with
Mycobacterium intracellulare
. Nine patients were resistant to clarithromycin. All 11 patients completed 18 months of follow-up. After 6 months of treatment, 45% (5/11) patients achieved culture conversion. However, after 18 months’ treatment, only 27% (3/11) maintained culture conversion. Chest CT imaging showed improvement in 5 patients, stability in 4 patients, and progression of lesions in 2 patients. The longest duration of bedaquiline use was 20 months. QTc interval prolongation was observed in 64% (7/11) of patients within 24 weeks, leading to permanent discontinuation of bedaquiline in one patient. The minimum inhibitory concentration (MIC) of bedaquiline ranged from ≤ 0.06 to 0.25 µg/mL prior to treatment, and two patients experienced an increase in MIC from ≤ 0.06 µg/mL to 0.12 µg/mL after treatment. The MICs of clofazimine were between 0.06 and 1 µg/mL.
Conclusion
The combination of bedaquiline and clofazimine may offer some clinical benefit in selected cases of advanced Mab and MAC lung diseases, but larger controlled studies are needed to confirm these preliminary findings.
Trial registration
This clinical study (ChiCTR2000037403) was registered on the Chinese Clinical Trial Registry website (
http://www.chictr.org.cn
) on August 28, 2020.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Analysis
/ Anemia
/ Antitubercular Agents - therapeutic use
/ Clofazimine - administration & dosage
/ Clofazimine - adverse effects
/ Clofazimine - therapeutic use
/ Diarylquinolines - administration & dosage
/ Diarylquinolines - adverse effects
/ Diarylquinolines - therapeutic use
/ Disease
/ Female
/ Humans
/ Lesions
/ Lung Diseases - drug therapy
/ Lung Diseases - microbiology
/ Male
/ Medicine
/ Minimum inhibitory concentration
/ Mycobacterium abscessus - drug effects
/ Mycobacterium avium Complex - drug effects
/ Mycobacterium Infections, Nontuberculous - drug therapy
/ Mycobacterium Infections, Nontuberculous - microbiology
/ Patients
/ Sputum
